High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR–directed monoclonal antibody (EXPAND trial) showing no prognostic impact
-
Published:2019-07
Issue:
Volume:116
Page:107-113
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Obermannova Radka,
Valik Dalibor,
Hasenclever Dirk,
Zdrazilova-Dubska Lenka,
Hacker Ulrich,
Demlova Regina,
Selingerova Iveta,
Lordick FlorianORCID
Funder
Czech Ministry of Health
Merck Serono GmbH
Subject
Cancer Research,Oncology
Reference34 articles.
1. Chemotherapy for advanced gastric cancer;Wagner,2010
2. Optimal chemotherapy for advanced gastric cancer: is there a global consensus?;Lordick;Gastric Cancer,2014
3. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010
4. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial;Lordick;Lancet Oncol,2013
5. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial;Waddell;Lancet Oncol,2013
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献